MA53438A - Vésicules extracellulaires ciblant des cellules dendritiques et utilisations associées - Google Patents
Vésicules extracellulaires ciblant des cellules dendritiques et utilisations associéesInfo
- Publication number
- MA53438A MA53438A MA053438A MA53438A MA53438A MA 53438 A MA53438 A MA 53438A MA 053438 A MA053438 A MA 053438A MA 53438 A MA53438 A MA 53438A MA 53438 A MA53438 A MA 53438A
- Authority
- MA
- Morocco
- Prior art keywords
- dendritic cells
- extracellular vesicles
- targeting dendritic
- targeting
- vesicles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6006—Cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2018/048026 WO2019040920A1 (fr) | 2017-08-25 | 2018-08-24 | Préparation d'exosomes thérapeutiques à l'aide de protéines membranaires |
| US201962870574P | 2019-07-03 | 2019-07-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53438A true MA53438A (fr) | 2021-09-15 |
Family
ID=69591350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053438A MA53438A (fr) | 2018-08-24 | 2019-08-23 | Vésicules extracellulaires ciblant des cellules dendritiques et utilisations associées |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20230181758A1 (fr) |
| EP (1) | EP3841112A1 (fr) |
| MA (1) | MA53438A (fr) |
| TW (1) | TW202024120A (fr) |
| WO (1) | WO2020041720A1 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4059510B1 (fr) * | 2018-11-16 | 2025-05-21 | Lonza Sales AG | Vésicules extracellulaires modifiées et leurs utilisations |
| WO2020215010A1 (fr) * | 2019-04-17 | 2020-10-22 | Codiak Biosciences, Inc. | Compositions d'exosomes et de virus adéno-associés |
| CA3142487A1 (fr) | 2019-06-04 | 2020-12-10 | Thomas Jefferson University | Vesicules extracellulaires derivees d'oligodendrocytes pour la therapie de la sclerose en plaques |
| JP7898376B2 (ja) * | 2019-08-06 | 2026-07-31 | オハイオ・ステイト・イノベーション・ファウンデーション | 治療用細胞外小胞 |
| WO2021237100A1 (fr) * | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Procédés d'administration ciblée de vésicules extracellulaires dans le poumon |
| CN112675298B (zh) * | 2020-12-28 | 2024-05-03 | 中国医学科学院医学生物学研究所 | 一种免疫佐剂、含有所述免疫佐剂的疫苗及制备方法和应用 |
| CA3226019A1 (fr) | 2021-07-20 | 2023-01-26 | Ags Therapeutics Sas | Vesicules extracellulaires provenant de microalgues, leur preparation et leurs utilisations |
| WO2023144127A1 (fr) | 2022-01-31 | 2023-08-03 | Ags Therapeutics Sas | Vésicules extracellulaires provenant de microalgues, leur biodistribution suite à leur administration, et leurs utilisations |
| WO2023232976A1 (fr) | 2022-06-03 | 2023-12-07 | Ags Therapeutics Sas | Vésicules extracellulaires provenant de microalgues génétiquement modifiées contenant une cargaison chargée de manière endogène, leur préparation et utilisations |
| WO2024014907A1 (fr) * | 2022-07-13 | 2024-01-18 | 주식회사 엠디뮨 | Vésicules dérivées de cellules modifiées par des protéines d'ancrage et leur utilisation |
| JP2025535944A (ja) | 2022-10-24 | 2025-10-30 | エイジーエス・セラピューティクス・ソシエテ・パール・アクシオン・サンプリフィエ | 微細藻類由来の細胞外小胞、鼻腔内投与時のそれらの生体内分布、及びそれらの使用 |
| KR20250110348A (ko) | 2022-11-23 | 2025-07-18 | 제이제이알앤디 엘엘씨 | 암 세포독성 엑소좀 제형 및 암 치료에 사용되는 방법 |
| WO2025176843A1 (fr) | 2024-02-21 | 2025-08-28 | Ags Therapeutics Sas | Vecteurs de thérapie génique à base de vésicules extracellulaires de microalgues (mev-gtvs), leur préparation et leurs utilisations |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US20050112141A1 (en) * | 2000-08-30 | 2005-05-26 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| CN105837690A (zh) * | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| EP2510946B1 (fr) | 2007-02-07 | 2015-08-05 | The Regents of The University of California | Conjugués d'agonistes synthétiques de tlr et leurs utilisations |
| GB0805159D0 (en) | 2008-03-19 | 2008-04-23 | Sancho Madrid David | Immune modulation via C-type lectin |
| WO2009026660A1 (fr) | 2007-08-30 | 2009-03-05 | Walter And Eliza Hall Institute Of Medical Research | Marqueur de cellules dendritiques et son utilisation |
| WO2009030996A1 (fr) | 2007-09-05 | 2009-03-12 | Coley Pharmaceutical Group, Inc. | Composés triazole utilisés comme agonistes du récepteur de type toll (tlr) |
| EP2200639B1 (fr) | 2007-09-24 | 2016-03-30 | Government of the USA, as Represented by the Secretary, Department of Health and Human Services | COMBINAISONS IMMUNOSTIMULANTES DE LIGANDS TLR3, TLR2 et TLR9 ET LEURS PROCÉDÉS D'UTILISATION |
| US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
| CA2732437C (fr) | 2008-08-01 | 2017-11-21 | Ventirx Pharmaceuticals, Inc. | Formulations d'agoniste des recepteurs de type toll et leur utilisation |
| JP2012521199A (ja) * | 2009-03-23 | 2012-09-13 | ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ | 免疫応答を調節するための化合物および方法 |
| EP2486134B1 (fr) | 2009-10-06 | 2014-01-08 | Panacela Labs, Inc. | Utilisation de récepteur de type toll et agoniste pour le traitement du cancer |
| CA2813494A1 (fr) | 2009-10-08 | 2011-04-14 | President And Fellows Of Harvard College | Procedes et compositions pour l'amelioration d'une maladie auto-immune utilisant des proteines de fusion d'un anticorps anti-recepteurs des cellules dendritiques avec des sequences peptidiques |
| KR101866893B1 (ko) | 2010-10-01 | 2018-06-14 | 벤티알엑스 파마슈티칼스 인코포레이티드 | Tlr 아고니스트의 치료적 용도 및 병용 요법 |
| WO2013053008A2 (fr) | 2011-10-14 | 2013-04-18 | The Walter And Eliza Hall Institute Of Medical Research | Molécules liant clec9a |
| EP2858722B8 (fr) | 2012-06-08 | 2018-02-21 | Aduro BioTech, Inc. | Compositions et procédés pour immunothérapie anticancéreuse |
| SG11201502796RA (en) | 2012-12-13 | 2015-05-28 | Aduro Biotech Inc | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| JP2016524593A (ja) | 2013-04-29 | 2016-08-18 | メモリアル スローン−ケタリング キャンサー センター | セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法 |
| CN105377867B (zh) | 2013-05-03 | 2019-11-12 | 加利福尼亚大学董事会 | I型干扰素的环状二核苷酸诱导 |
| EP2996472B1 (fr) | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions et procédés d'inhibition de la signalisation dépendante du « stimulateur des gènes interférons » |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| US10176292B2 (en) | 2013-07-31 | 2019-01-08 | Memorial Sloan-Kettering Cancer Center | STING crystals and modulators |
| JP2016538344A (ja) | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | 癌処置としてのstingアゴニストの使用 |
| EP3152217B1 (fr) | 2014-06-04 | 2018-08-01 | GlaxoSmithKline Intellectual Property Development Limited | Di-nucléotides cycliques utilisés comme modulateurs de sting |
| EP3233191A1 (fr) | 2014-12-16 | 2017-10-25 | Invivogen | Utilisation combinée d'un agent chimiothérapeutique et d'un dinucléotide cyclique pour le traitement du cancer |
| DK3233882T3 (da) | 2014-12-16 | 2020-01-27 | Kayla Therapeutics | Fluorinerede cykliske dinukleotider til cytokininduktion |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| TWI706958B (zh) | 2015-03-10 | 2020-10-11 | 美商艾杜諾生物科技公司 | 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法 |
| CN108137641B (zh) | 2015-08-13 | 2022-04-01 | 默沙东公司 | 作为sting激动剂的环状双核苷酸化合物 |
| KR20180066241A (ko) | 2015-10-28 | 2018-06-18 | 아두로 바이오테크, 인코포레이티드 | “인터페론 유전자의 자극제”-의존성 신호전달을 활성화시키기 위한 조성물 및 방법 |
| CN109071632B (zh) | 2016-02-05 | 2022-12-30 | 奥里尼斯生物科学私人有限公司 | 靶向性治疗剂及其用途 |
| IL280430B2 (en) | 2016-03-18 | 2023-11-01 | Univ Texas | Cyclic dinucleotide compounds and methods of use |
| WO2017175156A1 (fr) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Amides hétérocycliques utiles en tant que modulateurs de protéine |
| SG10201900628RA (en) | 2016-04-07 | 2019-02-27 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| WO2018100558A2 (fr) | 2016-12-01 | 2018-06-07 | Takeda Pharmaceutical Company Limited | Dinucléotide cyclique |
| CN117924493A (zh) | 2017-08-09 | 2024-04-26 | 奥里尼斯生物科学有限公司 | Clec9a结合剂及其用途 |
| KR20240033086A (ko) | 2017-08-25 | 2024-03-12 | 코디악 바이오사이언시즈, 인크. | 막 단백질을 사용한 치료용 엑소좀의 제조 |
-
2019
- 2019-08-23 WO PCT/US2019/047937 patent/WO2020041720A1/fr not_active Ceased
- 2019-08-23 EP EP19765396.7A patent/EP3841112A1/fr active Pending
- 2019-08-23 US US17/271,176 patent/US20230181758A1/en not_active Abandoned
- 2019-08-23 MA MA053438A patent/MA53438A/fr unknown
- 2019-08-26 TW TW108130488A patent/TW202024120A/zh unknown
-
2025
- 2025-12-15 US US19/419,609 patent/US20260216367A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230181758A1 (en) | 2023-06-15 |
| WO2020041720A1 (fr) | 2020-02-27 |
| TW202024120A (zh) | 2020-07-01 |
| EP3841112A1 (fr) | 2021-06-30 |
| US20260216367A1 (en) | 2026-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49971A (fr) | Vésicules extracellulaires modifiées et leurs utilisations | |
| EP3615046A4 (fr) | Cellules exprimant des récepteurs d'activation chimériques et des récepteurs de stimulation chimériques et utilisations associées | |
| IL259470A (en) | Neural cell extracellular vessicles | |
| EP3807321A4 (fr) | Constructions anti-mésothéline et utilisations associées | |
| CO2020004233A2 (es) | Vesículas extracelulares bacterianas | |
| MA46959A (fr) | Cellules b modifiées et compositions et méthodes associées | |
| HRP20260306T1 (hr) | Sredstva za poboljšanje stanične transfekcije i/ili proizvodnje raav vektora | |
| IL250042A0 (en) | Expanded tracking and advertising targeting of social networking users | |
| EP3612030A4 (fr) | Inhibiteurs d'indole ahr et leurs utilisations | |
| EP3380117A4 (fr) | Cellules génétiquement modifiées et utilisations de ces dernières | |
| EP3781196C0 (fr) | Ciblage de cellule in vivo spécifique à une séquence | |
| EP3362075A4 (fr) | Cellules tueuses naturelles et cellules ilc3, et leurs utilisations | |
| EP2882847A4 (fr) | Cellules tueuses naturelles et leurs utilisations | |
| EP4009989A4 (fr) | Vésicules extracellulaires thérapeutiques | |
| EP3710020A4 (fr) | Cellules immunoréactives sécrétant l'il-36 et utilisations associées | |
| EP3532605A4 (fr) | Génération améliorée de cellules de lignée musculaire et leurs utilisations thérapeutiques | |
| EP3307874A4 (fr) | Dérivation de cellules souches hépatiques et types de cellules hépatiques ainsi qu'utilisations associées | |
| EP3445381A4 (fr) | Production d'aav dans des cellules d'insectes, méthodes et compositions associées | |
| EP3313873A4 (fr) | Constructions ciblant des complexes peptide ny-eso-1/cmh et leurs utilisations | |
| EP3443506C0 (fr) | Neurone artificiel | |
| EP3413816A4 (fr) | Compositions hydratantes et utilisations associées | |
| DK3143134T3 (da) | Modificerede, naturlige dræberceller og anvendelser deraf | |
| MX364714B (es) | Animales no humanos geneticamente modificados y metodos de uso de los mismos. | |
| EP3630939A4 (fr) | Système de sélection de colonies de cellules | |
| UY34539A (es) | Heteroarilos y usos de los mismos |